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An update on heart failure: from
experimental findings to clinical trials
Thomas F. Lu¨scher, MD, FESC
Editor-in-Chief, Zurich Heart House, Careum Campus, Moussonstrasse 4, 8091 Zurich, Switzerland
Heart failure increasingly not only accounts for a significant part of car-
diovascular morbidity and mortality, but is also responsible for many
hospitalizations as outlined again in the most recent ESC Guidelines.1
Millions of patients worldwide are admitted for acute heart failure
each year, and physicians are confronted with the challenge of reduc-
ing symptoms while preventing end-organ dysfunction without causing
additional harm, and the intermediate-term challenges of improving
clinical outcomes such as hospital readmission and survival. Acute
heart failure therefore is an important new frontier for research and
clinical emergency management. A novel development are vasodilator
drugs, as discussed in detail in a clinical review ‘Agents with vaso-
dilator properties in acute heart failure’ by John R. Teerlink and
colleagues from the University of California San Francisco in
California, USA.2 Unfortunately, there are limited data supporting the
efficacy of currently available therapies. After diuretics, vasodilators
are the most common intravenous therapy, but neither nitrates, nitro-
prusside, nor nesiritide has evidence supporting their ability to provide
meaningful effects on clinical outcomes, except early symptom im-
provement. Recently, numerous novel agents with vasodilating prop-
erties have been developed, such as serelaxin,3 natriuretic peptides
such as ularitide4 and cenderitide, beta-arrestin-based angiotensin II
type 1 receptor ligands (TRV120027), nitroxyl donors (CXL-1020
abd CXL-1427), soluble guanylate cyclase modulators such as cinaci-
guat5 and vericiguat, short-acting calcium channel blockers such as cle-
vidipine, and the potassium channel activator nicorandil. These
development programmes range from the stage of early dose-finding
studies to large, multicentre mortality trials. There is an urgent need
for agents with vasodilating properties that will improve both in-
hospital and post-discharge clinical outcomes, and these novel
approaches may provide opportunities to address this need.
Triggers of acute heart failure are dietary mistakes, arrhythmias, es-
pecially atrial fibrillation,6 drugs, particularly non-steroidal anti-
inflammatory drugs (NSAIDs),7,8 and infections. Thus, vaccination in
patients with chronic heart failure might be a promising strategy to
avoid unnecessary hospitalizations. In a FAST TRACK entitled
‘Influenza vaccination and risk of hospitalization in patients
with heart failure: a self-controlled case series study’,9
Kazem Rahimi and colleagues from the University of Oxford in the
UK investigated the impact of influenza vaccination on the risk of hos-
pitalization in heart failure. To this end, they used linked primary and
secondary health records in England between 1990 and 2013. Using a
self-controlled case series design with conditional Poisson regression,
they estimated the incidence rate ratio of the number of hospitaliza-
tions in a year following vaccination with an adjacent vaccination-free
year in the same individuals. They found the uptake of vaccination to
be varied and generally low; only 49% in 2013. Among 59 202 heart
failure patients, influenza vaccination was associated with a lower risk
of hospitalization due to cardiovascular disease, with an odds ratio of
0.70, with more modest effects for hospitalization due to respiratory
infections, with an odds ratio of 0.84, and all-cause hospitalizations,
with an odds ratio of 0.96. The relative effects were greatest in
younger patients below the age of 66, with no difference between
men and women. In validation analyses, effects were not significant
for consecutive years without vaccination. This strongly suggests that
in heart failure, influenza vaccination is associated with reduced risk
of hospitalizations, especially for cardiovascular disease. Improved ef-
forts for a greater uptake of vaccination among heart failure patients
are thus needed. These clinically important findings are further dis-
cussed in an Editorial by Scott Solomon from the Brigham and
Women’s Hospital in Boston.10
Guidelines for the management of chronic heart failure use
randomized controlled trials to support treatment as the basis of
their recommendations. In a subsequent clinical manuscript ‘How
robust are clinical trials in heart failure?’, John J.J.V. McMurray
and colleagues from the Western Infirmary in Glasgow, UK11 remind
us that the significance of an observed treatment effect relies on the
use of a boundary P-value, most commonly P < 0.05. However,
whether we should rely on arbitrary threshold P-values to report re-
sults as ‘statistically significant’ has been repeatedly questioned. Thus,
the ‘fragility index’ has been proposed as an additional measure of the
robustness of trial findings. The fragility index is the minimum number
of events needing to change from a non-event to an event to render
a significant result non-significant. Hence, the authors calculated the
fragility index to examine the robustness of statistically significant
randomized controlled trials in chronic heart failure. Two reviewers
extracted data from randomized controlled trials supporting
Published on behalf of the European Society of Cardiology. All rights reserved. VC The Author 2017. For permissions, please email: journals.permissions@oup.com.
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treatment recommendations in chronic heart failure guidelines.
Twent-five eligible trials were identified, with a median sample size of
2331 patients and a median number of 689 primary endpoints. For
the primary endpoint, the median fragility index was 26 with a range
from 0 to 118. The fragility index was <_10 in a third of these 20 trials.
Of note, in one-fifth, the number of patients lost to follow-up in the
treatment group exceeded the fragility index. Thus, the results of
large randomized controlled trials in chronic heart failure hinge on a
small number of events. The fragility index offers an additional, easy
to understand metric, which augments the standard reporting of
boundary P-values for statistical significance. The fragility index helps
in the interpretation of the robustness of the results of randomized
controlled trials. The manuscript is accompanied by an interesting
Editorial by Rickey Edward Carter from the Mayo Clinic in
Rochester, Minnesota, the chief statistical editor of the European
Heart Journal.12
A less common form of heart failure is peripartum cardiomyop-
athy, which is also associated with a considerable risk.13,14 The benefit
of the b1-adrenergic receptor agonist dobutamine for treatment of
acute heart failure in peripartum cardiomyopathy is controversial.
Cardiac STAT3 is part of myocardial salvage pathways15 and its ex-
pression is reduced in peripartum cardiomyopathy patients. Mice car-
rying a cardiomyocyte-restricted deletion of STAT3, STAT3
knockout mice, develop peripartum cardiomyopathy. In a Basic
Science article entitled ‘Low STAT3 expression sensitizes to
toxic effects of b-adrenergic receptor stimulation in peri-
partum cardiomyopathy’, Denise Hilfiker-Kleiner and colleagues
from the Hannover Medical School in Germany hypothesized that
STAT3-dependent signalling networks may influence the response to
b1-adrenergic receptor agonists in peripartum cardiomyopathy pa-
tients and analysed this hypothesis in STAT3 knockout mice.16
Follow-up analyses in 27 patients with severe peripartum cardiomy-
opathy revealed that those not receiving dobutamine improved car-
diac function, while those receiving dobutamine ended up with heart
transplantation or assist devices. Of note, they displayed diminished
myocardial triglyceride, pyruvate, and lactate content compared with
non-failing controls. The b1-adrenergic receptor agonist iso-
proterenol induced heart failure with high mortality in post-partum
females, in non-pregnant females, and in male STAT3 knockout mice,
but not in wild-type littermates. Isoproterenol induced heart failure
and high mortality in STAT3 knockout mice by impairing fatty acid
and glucose uptake, thereby generating a metabolic deficit. The latter
was governed by disturbed STAT3-dependent signalling networks,
microRNA-199a-5p, microRNA7a-5p, insulin/glucose transporter-4,
and neuregulin/ErbB signalling. The resulting cardiac energy depletion
and oxidative stress promoted dysfunction of cardiomyocytes and
eventually heart failure, which could be attenuated by the b1-adren-
ergic receptor blocker metoprolol or glucose uptake-promoting
drugs such as perhexilline or etomoxir. The authors conclude that
isoproterenol impairs glucose uptake, and induces energy depletion,
oxidative stress, dysfunction, and death in STAT3-deficient cardio-
myocytes mainly via b1-adrenergic receptor stimulation. These cellu-
lar alterations may underlie the dobutamine-induced irreversible
progression of heart failure in peripartum cardiomyopathy patients
who frequently display reduced cardiac STAT3 expression.
Iron metabolism is important for myocardial function,17 and iron
deficiency is associated with adverse outcomes in heart failure, while
iron substitution improves quality of life and results of the 6-min
walking test.18,19 However, the underlying mechanisms are incom-
pletely understood. Intracellular iron availability is secured by two
mRNA-binding iron-regulatory proteins, IRP1 and IRP2. In another
Basic Science article, entitled ‘Iron-regulatory proteins secure
iron availability in cardiomyocytes to prevent heart failure’,
Tibor Kempf and colleagues from the Hannover Medical School in
Germany generated mice with a cardiomyocyte-targeted deletion of
iron-regulatory proteins Irp1 and Irp2 to explore the functional impli-
cations of iron deficiency in the heart independent of systemic iron
Figure 1 Summary of key findings. Iron-regulatory proteins (Irp1/
2) secure iron availability in cardiac myocytes by enhancing iron up-
take (via the transferrin receptor, Tfr1) and reducing iron export
(via ferroportin, Fpn) and storage (bound to ferritin, Ft). Under iron
replete conditions, enough iron is available to feed iron-sulphur
cluster-containing proteins required for mitochondrial oxidative
phosphorylation (OXPHOS). Reflecting net changes in iron uptake,
export, and storage, cardiomyocyte-selective Irp inactivation leads
to intracellular iron deficiency. Similarly, IRP activity is reduced in
the failing human heart. Iron deficiency in cardiomyocytes impairs
oxidative phosphorylation and adaptation to acute and chronic in-
creases in workload. Iron supplementation restores intracellular
iron availability by increasing Tfr1- and non-Tfr1-mediated iron up-
take, thereby enhancing oxidative phosphorylation and resistance
to stress (from Haddad S, Wang Y, Galy B, Korf-Klingebiel M,
Hirsch V, Baru AM, Rostami F, Reboll MR, Heineke J, Flo¨gel U,
Groos S, Renner A, Toischer K, Zimmermann F, Engeli S, Jordan J,
Bauersachs J, Hentze MW, Wollert KC, Kempf T. Iron-regulatory
proteins secure iron availability in cardiomyocytes to prevent heart
failure. See pages 362–372.)
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..deficiency or anaemia.20 Iron content in cardiomyocytes was reduced
in Irp-targeted mice. The animals were not anaemic nor did they
show a phenotype at baseline. Irp-targeted mice, however, were un-
able to increase left ventricular systolic function in response to an
acute dobutamine challenge. After myocardial infarction, Irp-targeted
mice developed more severe left ventricular dysfunction with
increased mortality. Mechanistically, the activity of the iron–sulphur
cluster-containing complex I of the mitochondrial electron transport
chain was reduced in left ventricles from Irp-targeted mice (Figure 1).
As demonstrated by extracellular flux analysis in vitro, mitochondrial
respiration was preserved at baseline but failed to increase in re-
sponse to dobutamine in Irp-targeted cardiomyocytes. As shown by
31P-magnetic resonance spectroscopy in vivo, the left ventricular
phosphocreatine/ATP ratio declined during dobutamine stress in Irp-
targeted mice, but remained stable in control mice. Intravenous injec-
tion of ferric carboxymaltose replenished cardiac iron stores,
restored mitochondrial respiratory capacity and inotropic reserve,
and attenuated adverse remodelling after myocardial infarction in Irp-
targeted mice but not in control mice. The authors conclude that
iron deficiency in cardiomyocytes impairs mitochondrial respiration
and adaptation to acute and chronic increases in workload. Iron sup-
plementation restores cardiac energy reserve and function in iron-
deficient hearts. The clinical implications of this experimental paper
are discussed in an Editorial by Gavin Oudit from University of
Alberta in Canada.17
The editors hope that this issue of the European Heart Journal will
be of interest to its readers.
References
1. Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JG, Coats AJ, Falk V,
Gonzalez-Juanatey JR, Harjola VP, Jankowska EA, Jessup M, Linde C,
Nihoyannopoulos P, Parissis JT, Pieske B, Riley JP, Rosano GM, Ruilope LM,
Ruschitzka F, Rutten FH, van der Meer P; Authors/Task Force Members. 2016
ESC Guidelines for the diagnosis and treatment of acute and chronic heart fail-
ure: the Task Force for the diagnosis and treatment of acute and chronic heart
failure of the European Society of Cardiology (ESC). Developed with the special
contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J
2016;37:2129–2200.
2. Singh A, Laribi S, Teerlink JR, Mebazaa A. Agents with vasodilator properties in
acute heart failure. Eur Heart J 2017;38:317–325.
3. Hernandez AV. Serelaxin: insights into its haemodynamic, biochemical, and clin-
ical effects in acute heart failure. Eur Heart J 2014;35:410–412.
4. Anker SD, Ponikowski P, Mitrovic V, Peacock WF, Filippatos G. Ularitide for the
treatment of acute decompensated heart failure: from preclinical to clinical stud-
ies. Eur Heart J 2015;36:715–723.
5. Erdmann E, Semigran MJ, Nieminen MS, Gheorghiade M, Agrawal R, Mitrovic V,
Mebazaa A. Cinaciguat, a soluble guanylate cyclase activator, unloads the heart
but also causes hypotension in acute decompensated heart failure. Eur Heart J
2013;34:57–67.
6. Bassand JP, Accetta G, Camm AJ, Cools F, Fitzmaurice DA, Fox KA, Goldhaber
SZ, Goto S, Haas S, Hacke W, Kayani G, Mantovani LG, Misselwitz F, Ten Cate
H, Turpie AG, Verheugt FW, Kakkar AK; GARFIELD-AF Investigators. Two-year
outcomes of patients with newly diagnosed atrial fibrillation: results from
GARFIELD-AF. Eur Heart J 2016;37:2882–2889.
7. Nissen SE, Yeomans ND, Solomon DH, Luscher TF, Libby P, Husni ME, Graham
DY, Borer JS, Wisniewski LM, Wolski KE, Wang Q, Menon V, Ruschitzka F,
Gaffney M, Beckerman B, Berger MF, Bao W, Lincoff AM; PRECISION Trial
Investigators. Cardiovascular safety of celecoxib, naproxen, or ibuprofen for
arthritis. N Engl J Med 2016;375:2519–2529.
8. MacDonald TM, Hawkey CJ, Ford I, McMurray JJ, Scheiman JM, Hallas J, Findlay E,
Grobbee DE, Hobbs FD, Ralston SH, Reid DM, Walters MR, Webster J,
Ruschitzka F, Ritchie LD, Perez-Gutthann S, Connolly E, Greenlaw N, Wilson A,
Wei L, Mackenzie IS. Randomized trial of switching from prescribed non-
selective non-steroidal anti-inflammatory drugs to prescribed celecoxib: the
Standard care vs. Celecoxib Outcome Trial (SCOT). Eur Heart J 2016; doi:
10.1093/eurheartj/ehw387.
9. Mohseni H, Kiran A, Khorshidi R, Rahimi K. Influenza vaccination and risk of hos-
pitalization in patients with heart failure: a self-controlled case series study. Eur
Heart J 2017;38:326–333.
10. Vardeny O, Solomon SD. Influenza vaccination: a one-shot deal to reduce car-
diovascular events. Eur Heart J 2017;38:334–337.
11. Docherty KF, Campbell RT, Jhund PS, Petrie MC, McMurray JJ. How robust are
clinical trials in heart failure? Eur Heart J 2017;38:338–345.
12. Carter RE, McKie PM, Storlie CB. The Fragility Index: a P-value in sheep’s cloth-
ing? Eur Heart J 2017;38:346–348.
13. Duncker D, Bauersachs J, Hilfiker-Kleiner D, Veltmann C. Underestimated risk
for life-threatening ventricular arrhythmias in newly diagnosed peripartum car-
diomyopathy? Eur Heart J 2015;36:1067–1068.
14. Hilfiker-Kleiner D, Haghikia A, Nonhoff J, Bauersachs J. Peripartum cardiomyop-
athy: current management and future perspectives. Eur Heart J
2015;36:1090–1097.
15. Akhmedov A, Montecucco F, Braunersreuther V, Camici GG, Jakob P, Reiner
MF, Glanzmann M, Burger F, Paneni F, Galan K, Pelli G, Vuilleumier N, Belin A,
Valle´e JP, Mach F, Lu¨scher TF. Genetic deletion of the adaptor protein p66Shc
increases susceptibility to short-term ischaemic myocardial injury via intracellular
salvage pathways. Eur Heart J 2015;36:516–526a.
16. Stapel B, Kohlhaas M, Ricke-Hoch M, Haghikia A, Erschow S, Knuuti J, Silvola JM,
Roivainen A, Saraste A, Nickel AG, Saar JA, Sieve I, Pietzsch S, Mu¨ller M, Bogeski
I, Kappl R, Jauhiainen M, Thackeray JT, Scherr M, Bengel FM, Hagl C, Tudorache
I, Bauersachs J, Maack C, Hilfiker-Kleiner D. Low STAT3 expression sensitizes to
toxic effects of b-adrenergic receptor stimulation in peripartum cardiomyopathy.
Eur Heart J 2017;38:349–361.
17. Zhabyeyev P, Oudit GY. Unravelling the molecular basis for cardiac iron metabol-
ism and deficiency in heart failure. Eur Heart J 2017;38:373–375.
18. Anker SD, Comin Colet J, Filippatos G, Willenheimer R, Dickstein K, Drexler H,
Lu¨scher TF, Bart B, Banasiak W, Niegowska J, Kirwan BA, Mori C, von Eisenhart
Rothe B, Pocock SJ, Poole-Wilson PA, Ponikowski P; FAIR-HF Trial Investigators.
Ferric carboxymaltose in patients with heart failure and iron deficiency. N Engl J
Med 2009;361:2436–2448.
19. Ponikowski P, van Veldhuisen DJ, Comin-Colet J, Ertl G, Komajda M, Mareev V,
Ruschitzka F, Anker SD; CONFIRM-HF Investigators. Beneficial effects of long-
term intravenous iron therapy with ferric carboxymaltose in patients with symp-
tomatic heart failure and iron deficiency. Eur Heart J 2015;36:657–668.
20. Haddad S, Wang Y, Galy B, Korf-Klingebiel M, Hirsch V, Baru AM, Rostami F,
Reboll MR, Heineke J, Flo¨gel U, Groos S, Renner A, Toischer K, Zimmermann F,
Engeli S, Jordan J, Bauersachs J, Hentze MW, Wollert KC, Kempf T. Iron-regula-
tory proteins secure iron availability in cardiomyocytes to prevent heart failure.
Eur Heart J 2017;38:362–372.
Issue @ a Glance 307
Downloaded from https://academic.oup.com/eurheartj/article-abstract/38/5/305/2990025
by guest
on 08 March 2018
